Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress 2023 EHA Congress 2023 ASCO Annual Meeting
Clinical Collections
Advances in Alzheimer’s

At a glance: The ONWARDS insulin icodec trials

A round-up of the ONWARDS phase 3 clinical trials evaluating the novel weekly insulin icodec in people with diabetes.
ADVANCED SEARCH
Log in
Top
BMC Public Health
Published in: BMC Public Health 1/2016

Open Access 01-12-2016 | Research article

Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States

Authors: Jemima A. Frimpong, Thomas D’Aunno, Stéphane Helleringer, Lisa R. Metsch

Published in: BMC Public Health | Issue 1/2016

Login to get access

Abstract

Background

To examine the extent to which state adoption of the Centers for Disease Control and Prevention (CDC) 2006 revisions to adult and adolescent HIV testing guidelines is associated with availability of other important prevention and medical services. We hypothesized that in states where the pretest counseling requirement for HIV testing was dropped from state legislation, substance use disorder treatment programs would have higher availability of HCV testing services than in states that had maintained this requirement.

Methods

We analyzed a nationally representative sample of 383 opioid treatment programs from the 2005 and 2011 National Drug Abuse Treatment System Survey (NDATSS). Data were collected from program directors and clinical supervisors through telephone surveys. Multivariate logistic regression models were used to measure associations between state adoption of CDC recommended guidelines for HIV pretest counseling and availability of HCV testing services.

Results

The effects of HIV testing legislative changes on HCV testing practices varied by type of opioid treatment program. In states that had removed the requirement for HIV pretest counseling, buprenorphine-only programs were more likely to offer HCV testing to their patients. The positive spillover effect of HIV pretest counseling policies, however, did not extend to methadone programs and did not translate into increased availability of on-site HCV testing in either program type.

Conclusions

Our findings highlight potential positive spillover effects of HIV testing policies on HCV testing practices. They also suggest that maximizing the benefits of HIV policies may require other initiatives, including resources and programmatic efforts that support systematic integration with other services and effective implementation.
Literature
1.
Branson BM, Handsfield HH, Lampe MA, Janssen RS, Taylor AW, Lyss SB, Clark JE, Centers for Disease C, Prevention. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep. 2006;55(RR-14):1–17. quiz CE11-14.
2.
Burke RC, Sepkowitz KA, Bernstein KT, Karpati AM, Myers JE, Tsoi BW, Begier EM. Why don’t physicians test for HIV? A review of the US literature. AIDS. 2007;21(12):1617–24.CrossRefPubMed
3.
Bokhour BG, Solomon JL, Knapp H, Asch SM, Gifford AL. Barriers and facilitators to routine HIV testing in VA primary care. J Gen Intern Med. 2009;24(10):1109–14.CrossRefPubMedPubMedCentral
4.
Farnham PG, Hutchinson AB, Sansom SL, Branson BM. Comparing the costs of HIV screening strategies and technologies in health-care settings. Public Health Rep. 2008;123 Suppl 3:51–62.CrossRefPubMedPubMedCentral
5.
Metsch LR, Feaster DJ, Gooden L, Schackman BR, Matheson T, Das M, Golden MR, Huffaker S, Haynes LF, Tross S, et al. Effect of risk-reduction counseling with rapid HIV testing on risk of acquiring sexually transmitted infections: the AWARE randomized clinical trial. JAMA. 2013;310(16):1701–10.CrossRefPubMedPubMedCentral
6.
Metsch LR, Feaster DJ, Gooden L, Matheson T, Mandler RN, Haynes L, Tross S, Kyle T, Gallup D, Kosinski AS, et al. Implementing rapid HIV testing with or without risk-reduction counseling in drug treatment centers: results of a randomized trial. Am J Public Health. 2012;102(6):1160–7.CrossRefPubMedPubMedCentral
7.
Mahajan AP, Stemple L, Shapiro MF, King JB, Cunningham WE. Consistency of state statutes with the Centers for Disease Control and Prevention HIV testing recommendations for health care settings. Ann Intern Med. 2009;150(4):263–9.CrossRefPubMedPubMedCentral
8.
Neff S, Goldschmidt R. Centers for Disease Control and Prevention 2006 human immunodeficiency virus testing recommendations and state testing laws. JAMA. 2011;305(17):1767–8.CrossRefPubMed
9.
D’Aunno T, Pollack HA, Jiang L, Metsch LR, Friedmann PD. HIV Testing in the Nation’s opioid treatment programs, 2005–2011: the role of state regulations. Health Serv Res. 2014;49(1):230–48.CrossRefPubMed
10.
Zetola NM, Grijalva CG, Gertler S, Hare CB, Kaplan B, Dowling T, Colfax G, Katz MH, Klausner JD. Simplifying consent for HIV testing is associated with an increase in HIV testing and case detection in highest risk groups, San Francisco January 2003-June 2007. PLoS One. 2008;3(7):e2591.CrossRefPubMedPubMedCentral
11.
Haukoos JS, Hopkins E, Byyny RL. Patient acceptance of rapid HIV testing practices in an urban emergency department: assessment of the 2006 CDC recommendations for HIV screening in health care settings. Ann Emerg Med. 2008;51(3):303–309, 309 e301.CrossRefPubMed
12.
Paltiel AD, Walensky RP, Schackman BR, Seage IIIGR, Mercincavage LM, Weinstein MC, Freedberg KA. Expanded HIV screening in the United States: effect on clinical outcomes, HIV transmission, and costs. Ann Intern Med. 2006;145(11):797–806.CrossRefPubMed
13.
Nayak SU, Welch ML, Kan VL. Greater HIV testing after Veterans Health Administration policy change: the experience from a VA Medical Center in a high HIV prevalence area. J Acquir Immune Defic Syndr. 2012;60(2):165–8.CrossRefPubMed
14.
15.
Kresina TF, Bruce RD, Cargill VA, Cheever LW. Integrating care for hepatitis C virus (HCV) and primary care for HIV for injection drug users coinfected with HIV and HCV. Clin Infect Dis. 2005;41(Supplement 1):S83–8.CrossRefPubMed
16.
Centers for Disease Control and Prevention. Integrated prevention services for HIV infection, viral hepatitis, sexually transmitted diseases, and tuberculosis for persons who use drugs illicitly: summary guidance from CDC and the U.S. Department of Health and Human Services. MMWR Recomm Rep. 2012;61(rr05):1–40.
17.
Hernandez MD, Sherman KE. HIV/HCV Coinfection natural history and disease progression, a review of the most recent literature. Curr Opin HIV AIDS. 2011;6(6):478–82.CrossRefPubMedPubMedCentral
18.
Rotman Y, Liang TJ. Coinfection with hepatitis C virus and human immunodeficiency virus: virological, immunological, and clinical outcomes. J Virol. 2009;83(15):7366–74.CrossRefPubMedPubMedCentral
19.
Volkow ND, Montaner J. The urgency of providing comprehensive and integrated treatment for substance abusers with HIV. Health Aff (Millwood). 2011;30(8):1411–9.CrossRef
20.
Stopka TJ, Marshall C, Bluthenthal RN, Webb DS, Truax SR. HCV and HIV Counseling and testing integration in California: an innovative approach to increase HIV counseling and testing rates. Public Health Rep. 2007;122 Suppl 2:68–73.CrossRefPubMedPubMedCentral
21.
Schackman BR, Leff JA, Barter DM, DiLorenzo MA, Feaster DJ, Metsch LR, Freedberg KA, Linas BP. Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs. Addiction. 2015;110(1):129–43.CrossRefPubMedPubMedCentral
22.
Substance Abuse and Mental Health Services Administration. The N-SSATS Report: Trends in the Use of Methadone and Buprenorphine at Substance Abuse Treatment Facilities: 2003 to 2011. Rockville: Substance Abuse and Mental Health Services Administration; 2012.
23.
Centers for Disease Control and Prevention. HIV and Viral Hepatitis. In: National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention. 2014.
24.
Centers for Disease Control & Prevention (CDC). HIV Prevalence estimates — United States, 2006. Morb Mortal Wkly Rep. 2008;57(39):1073–6.
25.
Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus prevalence and outcomes among injecting drug users on opioid replacement therapy. J Gastroenterol Hepatol. 2005;20(7):1082–6.CrossRefPubMed
26.
Chitwood DD, Sanchez J, Comerford M, McCoy CB. Primary preventive health care among injection drug users, other sustained drug users, and non-users. Subst Use Misuse. 2001;36(6-7):807–24.CrossRefPubMed
27.
Ostertag S, Wright BRE, Broadhead RS, Altice FL. Trust and other characteristics associated with health care utilization by injection drug users. J Drug Issues. 2006;36(4):953–74.CrossRef
28.
Andrews CM, D’Aunno TA, Pollack HA, Friedmann PD. Adoption of evidence-based clinical innovations: the case of buprenorphine use by opioid treatment programs. Med Care Res Rev. 2014;71(1):43–60.CrossRefPubMed
29.
Frimpong JA, D’Aunno T, Jiang L. Determinants of the availability of hepatitis C testing services in opioid treatment programs: results from a national study. Am J Public Health. 2014;104(6):e75–82.CrossRefPubMedPubMedCentral
30.
Pollack HA, D’Aunno T. HIV testing and counseling in the nation’s outpatient substance abuse treatment system, 1995–2005. J Subst Abuse Treat. 2010;38(4):307–16.CrossRefPubMed
31.
32.
Wolf LE, Lo B, Gostin LO. Legal barriers to implementing recommendations for universal, routine prenatal HIV testing. J Law Med Ethics. 2004;32(1):137–47.CrossRefPubMed
33.
34.
D’Aunno T. The role of organization and management in substance abuse treatment: Review and roadmap. J Subst Abuse Treat. 2006;31(3):221–33.CrossRefPubMed
35.
Fields D, Roman PM, Blum TC. Management systems, patient quality improvement, resource availability, and substance abuse treatment quality. Health Serv Res. 2012;47(3 PART 1):1068–90.CrossRefPubMed
36.
Long J, Freese J. Regression Models for Categorical Dependent Variables Using Stata. 2nd ed. College Station: Stata Press; 2006.
37.
Hsiao C. Analysis of panel data. 2nd ed. Cambridge: Cambridge University Press; 2003.CrossRef
38.
Edelman EJ, Dinh AT, Moore BA, Schottenfeld RS, Fiellin DA, Sullivan LE. Human immunodeficiency virus testing practices among buprenorphine-prescribing physicians. J Addict Med. 2012;6(2):159–65.CrossRefPubMedPubMedCentral
39.
Wells R, Lemak CH, D’Aunno TA. Organizational survival in the outpatient substance abuse treatment sector, 1988-2000. Med Care Res Rev. 2005;62(6):697–719.CrossRefPubMed
40.
Knudsen HK, Ducharme LJ, Roman PM. Early adoption of buprenorphine in substance abuse treatment centers: data from the private and public sectors. J Subst Abuse Treat. 2006;30(4):363–73.CrossRefPubMed
41.
Ducharme LJ, Knudsen HK, Roman PM, Johnson JA. Innovation adoption in substance abuse treatment: exposure, trialability, and the Clinical Trials Network. J Subst Abuse Treat. 2007;32(4):321–9.CrossRefPubMedPubMedCentral
42.
43.
Hansen HB, Siegel CE, Case BG, Bertollo DN, DiRocco D, Galanter M. Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York city. J Behav Health Serv Res. 2013;40(3):367–77.CrossRefPubMed
44.
45.
Coil CJ, Haukoos JS, Witt MD, Wallace RC, Lewis RJ. Evaluation of an emergency department referral system for outpatient HIV testing. J Acquir Immune Defic Syndr. 2004;35(1):52–5.CrossRefPubMed
46.
47.
Smith BD, Drobeniuc J, Jewett A, Branson BM, Garfein RS, Teshale E, Kamili S, Weinbaum CM. Evaluation of three rapid screening assays for detection of antibodies to hepatitis C virus. J Infect Dis. 2011;204(6):825–31.CrossRefPubMed
48.
San Antonio-Gaddy M, Richardson-Moore A, Burstein GR, Newman DR, Branson BM, Birkhead GS. Rapid HIV antibody testing in the New York State Anonymous HIV Counseling and Testing Program: experience from the field. J Acquir Immune Defic Syndr. 2006;43(4):446–50.CrossRefPubMed
49.
Spielberg F, Branson BM, Goldbaum GM, Lockhart D, Kurth A, Celum CL, Rossini A, Critchlow CW, Wood RW. Overcoming barriers to HIV testing: preferences for new strategies among clients of a needle exchange, a sexually transmitted disease clinic, and sex venues for men who have sex with men. J Acquir Immune Defic Syndr. 2003;32(3):318–27.CrossRefPubMed
50.
Thornton AC, Delpech V, Kall MM, Nardone A. HIV testing in community settings in resource-rich countries: a systematic review of the evidence. HIV Med. 2012;13(7):416–26.CrossRefPubMed
51.
Pottie K, Dahal G, Logie C, Welch V. Rapid testing for improving uptake of HIV/AIDS services in people with HIV infection. Cochrane Database Syst Rev. 2011;11(CD003507):1–8.
52.
Freeman AE, Sattin RW, Miller KM, Dias JK, Wilde JA. Acceptance of rapid HIV screening in a southeastern emergency department. Acad Emerg Med. 2009;16(11):1156–64.CrossRefPubMed
53.
Drobnik A, Judd C, Banach D, Egger J, Konty K, Rude E. Public health implications of rapid hepatitis C screening with an oral swab for community-based organizations serving high-risk populations. Am J Public Health. 2011;101(11):2151–5.CrossRefPubMedPubMedCentral
54.
Frimpong JA, D’Aunno T, Perlman DC, Strauss SM, Mallow A, Hernandez D, Schackman BR, Feaster DJ, Metsch LR. On-site bundled rapid HIV/HCV testing in substance use disorder treatment programs: study protocol for a hybrid design randomized controlled trial. Trials. 2016;17:117.CrossRefPubMedPubMedCentral
55.
Smith BD, Morgan RL, Beckett GA, Falck-Ytter Y, Holtzman D, Teo CG, Jewett A, Baack B, Rein DB, Patel N, et al. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945-1965. MMWR Recomm Rep. 2012;61(RR-4):1–32.PubMed
56.
Kohli A, Shaffer A, Sherman A, Kottilil S. Treatment of hepatitis C: a systematic review. JAMA. 2014;312(6):631–40.CrossRefPubMed
57.
Yehia BR, Schranz AJ, Umscheid CA, Lo Re III V. The treatment cascade for chronic hepatitis C virus infection in the United States: a systematic review and meta-analysis. PLoS One. 2014;9(7):e101554.CrossRefPubMedPubMedCentral
58.
Holtgrave DR. Costs and consequences of the US centers for disease control and prevention’s recommendations for Opt-Out HIV testing. PLoS Med. 2007;4(6):e194.CrossRefPubMedPubMedCentral
59.
Du P, Camacho F, Zurlo J, Lengerich EJ. Human immunodeficiency virus testing behaviors among US adults: the roles of individual factors, legislative status, and public health resources. Sex Transm Dis. 2011;38(9):858–64.CrossRefPubMedPubMedCentral
60.
Fenton KA. Changing epidemiology of HIV/AIDS in the United States: implications for enhancing and promoting HIV testing strategies. Clin Infect Dis. 2007;45 Suppl 4:S213–220.CrossRefPubMed
61.
Branson B. Current HIV epidemiology and revised recommendations for HIV testing in health-care settings. J Med Virol. 2007;79 Suppl 1:S6–10.CrossRefPubMed
62.
63.
64.
65.
Meyer JP, Moghimi Y, Marcus R, Lim JK, Litwin AH, Altice FL. Evidence-based interventions to enhance assessment, treatment, and adherence in the chronic Hepatitis C care continuum. Int J Drug Policy. 2015;26(10):922–35.CrossRefPubMedPubMedCentral
Metadata
Title
Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States
Authors
Jemima A. Frimpong
Thomas D’Aunno
Stéphane Helleringer
Lisa R. Metsch
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Public Health / Issue 1/2016
Electronic ISSN: 1471-2458
DOI
https://doi.org/10.1186/s12889-016-3322-4

Other articles of this Issue 1/2016

BMC Public Health 1/2016 Go to the issue

Erratum

Erratum to: The effectiveness of non-pyrethroid insecticide-treated durable wall lining to control malaria in rural Tanzania: study protocol for a two-armed cluster randomized trial

Research article

The health beliefs of mothers about preventing cervical cancer and their intention to recommend the Pap test to their daughters: a cross-sectional survey

Research article

Modifying effects of education on the association between lifestyle behaviors and the risk of obesity: evidence from South Korea

Research article

Essential conditions for the implementation of comprehensive school health to achieve changes in school culture and improvements in health behaviours of students

Research article

The associations between domain-specific sedentary behaviours and dietary habits in European adults: a cross-sectional analysis of the SPOTLIGHT survey

Research article

Making the invisible visible: a systematic review of sexual minority women’s health in Southern Africa